B. Riley Financial Boosts KindlyMD (NASDAQ:NAKA) Price Target to $11.00

KindlyMD (NASDAQ:NAKA) had its target price increased by equities researchers at B. Riley Financial from $9.00 to $11.00 in a report released on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock. B. Riley Financial’s target price would indicate a potential upside of 33.66% from the company’s previous close.

A number of other research analysts have also recently commented on the stock. TD Cowen increased their target price on shares of KindlyMD from $1.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, July 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of KindlyMD in a report on Friday, August 7th. Finally, Wall Street Zen upgraded shares of KindlyMD to a “sell” rating in a report on Saturday, May 23rd. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, KindlyMD presently has a consensus rating of “Hold” and an average target price of $19.33.

KindlyMD Trading Up 7.2%

Shares of NAKA stock traded up $0.55 during trading hours on Thursday, hitting $8.23. 125,402 shares of the company were exchanged, compared to its average volume of 197,320. The business has a 50 day moving average of $5.04 and a two-hundred day moving average of $6.95. KindlyMD has a 52 week low of $3.33 and a 52 week high of $343.20. The company has a market capitalization of $147.28 million, a PE ratio of -0.23 and a beta of 15.99.

KindlyMD (NASDAQ:NAKA) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($6.65) earnings per share (EPS) for the quarter. KindlyMD had a negative return on equity of 63.45% and a negative net margin of 1,067.93%.The firm had revenue of $35.87 million for the quarter. On average, research analysts forecast that KindlyMD will post -11.31 EPS for the current year.

Insider Activity at KindlyMD

In other news, CEO David F. Bailey bought 4,852 shares of the stock in a transaction dated Thursday, August 20th. The shares were bought at an average cost of $6.27 per share, with a total value of $30,422.04. Following the completion of the transaction, the chief executive officer directly owned 3,185,246 shares of the company’s stock, valued at $19,971,492.42. This trade represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders purchased a total of 41,904 shares of company stock worth $235,231 in the last ninety days. Insiders own 24.49% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. State Street Corp bought a new position in KindlyMD in the 4th quarter worth approximately $593,000. Geode Capital Management LLC boosted its holdings in KindlyMD by 76.2% during the 2nd quarter. Geode Capital Management LLC now owns 19,394 shares of the company’s stock valued at $484,000 after acquiring an additional 8,386 shares during the period. NewEdge Advisors LLC bought a new position in KindlyMD during the 4th quarter worth approximately $316,000. Osaic Holdings Inc. purchased a new position in KindlyMD in the 2nd quarter worth approximately $215,000. Finally, Invesco Ltd. bought a new stake in KindlyMD in the fourth quarter valued at approximately $211,000.

KindlyMD Company Profile

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.